Nature Reviews Cancer contents February Volume 12 Number 2 pp 79-149

Advertisement
In Vivo Cultrex BME Matrix The In Vivo use of Cultrex BME or HC20+ BME PathClear is shown to improve tumor take and growth in subcutaneous or orthotopic locations and to promote xenograft tissue transplantation. Trevigen's BME contains very low levels of endotoxins and is clear of 31 organisms and viruses. Order today on trevigen.com and enter CULTREX2012 for 20% off.
TABLE OF CONTENTS
February 2012 Volume 12 Number 2		Advertisement
Impact Factor 37.178 *	In this issue Research Highlights Progress Reviews Perspectives Correspondence Also this month Article series: Genomic instability in cancer The next 10 years  Featured article: Targeting MET in cancer: rationale and progress Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier & George Vande Woude	Complete Genomics Cancer Sequencing Service Make use of paired tumor/normal samples for your whole human genome sequencing projects by using the Complete Genomics Cancer Sequencing Service. Listen to Dr. Sharoni Jacobs, Senior Product Manager; discuss how both the complexities of heterogeneous samples are addressed and the advanced algorithms used in our analysis pipeline for highest quality results.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Reviews Cancer POSTER - Proteasome inhibition and cancer therapy Author: Q. Ping Dou This poster highlights recent achievements and progress in targeting the ubiquitin-proteasome degradation pathway for cancer therapy. Access the Poster FREE online! www.nature.com/nrc/posters/proteasome This Poster is freely available thanks to sponsorship from Onyx Pharmaceuticals, Inc.
RESEARCH HIGHLIGHTS Top Breast cancer: Reprogramming ERα p79 | doi:10.1038/nrc3209 This paper maps oestrogen receptor-α (ERα) binding to chromatin in frozen samples of breast tumours to identify changes in ERα-mediated gene expression, which are modulated by FOXA1 and which correlate with prognosis. PDF Angiogenesis: What's the alternative? p80 | doi:10.1038/nrc3207 Regulation of a splicing factor kinase by the Wilms' tumour suppressor WT1 contributes to alternative splicing of VEGFA. PDF Signalling: SRC and survival p80 | doi:10.1038/nrc3208 Cancer cells target active SRC for autophagy when SRC signalling is deregulated through the loss of focal adhesion kinase. PDF Retinoblastoma: Epigenetic outcome p80 | doi:10.1038/nrc3222 Whole-genome sequencing indicates few genetic changes in retinoblastoma and hints at epigenetic changes instead. PDF Cancer stem cells: TAZ takes centre stage p82 | doi:10.1038/nrc3210 Two papers indicate the importance of TAZ in cancer biology. PDF Therapeutics: Keeping one step ahead p82 | doi:10.1038/nrc3211 A recent study proposes a new drug combination strategy to target drug-resistant chronic myeloid leukaemia. PDF TRIAL WATCH Bevacizumab in ovarian cancer p83 | doi:10.1038/nrc3213 PDF IN BRIEF Therapeutics: Mosaic glioblastoma | Signalling: Wild type and mutant combine | Metastasis: A new protector? | Metastasis: Building a niche PDF Cancer JOBS of the week Postdoctoral research fellow University of Texas MD Anderson Cancer Center Post-doctoral Training Fellow - Structural Biology The Institute of Cancer Research Hematology Oncology Consultant, Hematology - Spokane Job Celgene Corporation Independent Research Fellowships in Biomedical and Veterinary Sciences University of Bristol Postdoctoral Fellow - Gastrointestinal Cancer University of British Columbia More Science jobs from Cancer EVENT 10th International Congress on Targeted Anticancer Therapies 08.-10.03.12 Amsterdam, Netherlands More science events from
Erratum: Metabolism: Catabolic effects Sarah Seton-Rogers p83 | doi:10.1038/nrc3221 Full Text | PDF
PROGRESS		Top
Are snoRNAs and snoRNA host genes new players in cancer? Gwyn T. Williams & Farzin Farzaneh p84 | doi:10.1038/nrc3195 The primary role for small nucleolar RNAs (snoRNAs) has typically been considered to be the guiding of the post-transcriptional modifications of particular RNAs. This Progress article discusses the intriguing recent findings that various snoRNAs, and the host genes that encode them, could have previously unsuspected and varied roles in cancer. Abstract | Full Text | PDF
REVIEWS		Top
Targeting MET in cancer: rationale and progress Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier & George Vande Woude p89 | doi:10.1038/nrc3205 Signalling through the receptor tyrosine kinase MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) has been associated with various types of cancer, which has led to numerous efforts to try and target these proteins. This Review discusses HGF/SF–MET signalling in cancer and current progress with targeting this pathway. Abstract | Full Text | PDF
Article series: Genomic instability in cancer Balancing repair and tolerance of DNA damage caused by alkylating agents Dragony Fu, Jennifer A. Calvo & Leona D. Samson p104 | doi:10.1038/nrc3185 Alkylating agents can both induce tumorigenesis and be used to treat cancer patients. However, responses to alkylating chemotherapeutic drugs are variable. This Review discusses the molecular responses to alkylating agents and the causes for such variation. Abstract | Full Text | PDF
Article series: The next 10 years The diverse and complex roles of NF-κB subunits in cancer Neil D. Perkins p121 | doi:10.1038/nrc3204 Nuclear factor-κB (NF-κB) has many functions in cancer, hence the need for drugs that can modulate its activity. In order to achieve this, Neil D. Perkins argues that the complex roles of the individual NF-κB subunits must be considered. Abstract | Full Text | PDF
Advertisement
Accurately measure subcutaneous tumors Preclinical oncology studies can provide invaluable information, but calipers are cumbersome to use and notoriously inaccurate. The TumorImager™ rapidly scans subcutaneous tumors (~1 sec) without requiring anesthesia, providing highly sensitive, reproducible measurements of drug response. TumorManagerTM can handle all aspects of your study from protocol design to analysis. For more information or free web demo: www.biopticon.com/tumorImager.php
PERSPECTIVES		Top
TIMELINE Cancer stem cells: an evolving concept Long V. Nguyen, Robert Vanner, Peter Dirks & Connie J. Eaves p133 | doi:10.1038/nrc3184 There is increasing debate about what is meant by the term 'cancer stem cell' (CSC) and the degree to which the concept of CSCs can provide insights into cancer biology and therapy. This Timeline article traces the historical milestones in normal and cancer stem cell biology as a backdrop to a discussion of how these fields have informed each other. Abstract | Full Text | PDF
OPINION Mouse models of cancer: does the strain matter? Kent W. Hunter p144 | doi:10.1038/nrc3206 Although mouse models have improved our understanding of cancer biology, their inbred nature does not accurately model the inherited variability in human populations that can influence cancer susceptibility and outcomes. This Opinion article discusses how inherited variability influences cancer phenotypes, how it can confound experiments and how it can be exploited to reveal new truths about cancer biology. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: On the evidence for ESR1 amplification in breast cancer Frederik Holst, Cathy B. Moelans, Martin Filipits, Christian F. Singer, Ronald Simon & Paul J. van Diest p149 | doi:10.1038/nrc3093-c3 Full Text | PDF
Advertisement
Nature Reprint Collection: microRNAs This collection of recent papers from Nature and other NPG journals highlights developments in microRNA biology and effects on gene regulation. Access the reprint collection free online for six months. Produced with support from: Regulus Therapeutics Inc.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.